该试验预计将于2022年启动,其结果将为TAEUS装置在中国用于NAFLD的潜在商业化提供临床证据。
ENDRA(NDRA)首席执行官弗朗索瓦·米其隆(Francois Michelon)表...查看全文
智通财经APP预告,2021年5月18日,港美股上市公司活动及香港重要财经会议信息情况如下: 04:30 ENDRA Life Sciences, Inc.(NDRA.US) ENDRA Life Sciences, Inc.(NDRA.US)2021年第一季度业绩电话会 网络转播 04:30 GAN Limited(GAN.US) G... 网页链接
$Endra Life Sciences(NDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-032219 Size: 4 KB 网页链接
$Endra Life Sciences(NDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-031895 Size: 5 KB 网页链接
$Endra Life Sciences(NDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-031547 Size: 4 KB 网页链接
$Endra Life Sciences(NDRA)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001654954-20-005509 Act: 34 Size: 3 MB 网页链接
$Endra Life Sciences(NDRA)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001654954-20-005473 Act: 34 Size: 224 KB 网页链接
$Endra Life Sciences(NDRA)$ DEF 14A Other definitive proxy statements Accession Number: 0001654954-20-004632 Act: 34 Size: 600 KB 网页链接
$Endra Life Sciences(NDRA)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001654954-20-004633 Act: 34 Size: 65 KB 网页链接
$Endra Life Sciences(NDRA)$ 8-K Current report, items 1.01, 2.03, and 3.01 Accession Number: 0001654954-20-004473 Act: 34 Size: 36 KB 网页链接
$Endra Life Sciences(NDRA)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-20-024483 Size: 7 KB 网页链接